The Patent Finder

Terms ending in 2041

Genmab A/S

Every in-force patent on Genmab A/S's record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 12,570,751Binding Agents Binding to PD-L1 and CD137 and Use Thereof
In force
 · Medium confidence
Genmab A/SIn forceMedium confidence
US 12,324,841Methods of Treating Cancer with a Combination of an ANTI-PD-1 Antibody and an Anti-Tissue Factor Antibody-Drug Conjugate
In force
 · High confidence
MSD International GmbHIn forceHigh confidence
US 12,415,859Methods of Producing Heterodimeric Antibodies
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 11,261,254Antibodies
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 12,435,154Bispecific Antibodies Against CD3 and CD20
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 11,535,679Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Follicular Lymphoma
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 11,548,952Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 11,608,383Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Follicular Lymphoma
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 11,845,805Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 11,858,995Bispecific Antibodies Against CD3 and CD20 for Treating Chronic Lymphocytic Leukemia
In force
 · High confidence
Genmab A/SIn forceHigh confidence
1 more term end in 2041 · Pro
10 of 11 patents shown. Soonest term end first, then patent number.
Pro members see all 11.
Upgrade to Pro
10 of these are in force and held by Genmab A/S.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited